Kymera Investor Presentation Deck

TARGET SELECTION Undrugged (UD) or inadequately drugged (ID) targets UD Transcription Factors (e.g. STAT3) ID Degrader Advantage Over SMI (e.g. IRAK4, MDM2) KYMERA Kymera's Differentiated Approach to TPD CLINICAL TRANSLATION Strong genetic validation within clinically validated pathway PLATFORM Significantly differentiated investments Tissue- selective E3 Ligases Enabling a whole new generation of clinical programs ©2023 KYMERA THERAPEUTICS, INC. New Molecular Glue Approach Novel strategy to address undrugged/ un-ligandable targets Fidelity of translation of PK, PD and safety now in 3 programs in immunology and oncology Percent Change from Baseline IRAK4 Percent Change from Baseline -20 -100 0 -20- -40- -80 -100- 0 4 0 8 12 16 20 24 28 32 36 40 2 24 96 192 15 Hours Days MAD PART C 0 2 24 192 15 Hours: Days ● TPD "FIRSTS" Accomplished several "firsts" in TPD: FIRST randomized, placebo- controlled trial in healthy volunteers with KT-474 (IRAK4) FIRST heterobifunctional degrader with clinical activity, outside of oncology, in patients with HS and AD with KT-474 (IRAK4) FIRST demonstration of biological and clinical differentiation of degrader vs SMI with KT-474 (IRAK4) FIRST heterobifunctional degrader against an undrugged transcription factor in clinic with KT-333 (STAT3) PAGE 4

View entire presentation